Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

208
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
208
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

279
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
279
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

302
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
302
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

975
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
975
Drug Therapy01:28

Drug Therapy

316
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
316
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

1.1K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survodutide Once Weekly for the Treatment of Adults with Obesity.

The New England journal of medicine·2026
Same author

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial.

Nature medicine·2026
Same author

Correction: Weight-related changes in MRI-derived measures of body composition and liver steatosis: a large-scale analysis for obesity trial design.

International journal of obesity (2005)·2026
Same author

The Future of Obesity Care: Exploring Synergies Between Metabolic Bariatric Surgery, Interventional Endoscopy and Pharmacotherapy.

Obesity surgery·2026
Same author

Weight-related changes in MRI-derived measures of body composition and liver steatosis: a large-scale analysis for obesity trial design.

International journal of obesity (2005)·2026
Same author

Survodutide for the Treatment of Obesity: Baseline Characteristics of the SYNCHRONIZE Cardiovascular Outcomes Trial.

JACC. Heart failure·2025

Related Experiment Video

Updated: Feb 19, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.3K

Pharmacologic therapies for obesity.

Lee M Kaplan1

  • 1MGH Weight Center and Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, 50 Staniford Street, Boston, MA 02114, USA. LMKaplan@partners.org

Gastroenterology Clinics of North America
|March 6, 2010
PubMed
Summary

Pharmacological therapy for obesity is evolving, with FDA-approved options and repurposed drugs offering new treatment avenues. Effective obesity management requires a multifaceted approach combining various therapies for individual patient needs.

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.6K
Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.7K

Related Experiment Videos

Last Updated: Feb 19, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.3K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

1.6K
Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.7K

Area of Science:

  • Pharmacology
  • Endocrinology
  • Metabolic Diseases

Background:

  • Obesity is a complex, multifactorial chronic disease.
  • Weight regulation involves intricate and redundant physiological systems.
  • Current obesity treatments often require combination strategies.

Purpose of the Study:

  • To review current pharmacological therapies for obesity.
  • To examine Food and Drug Administration (FDA)-approved medications.
  • To explore off-label drug use for obesity management.

Main Methods:

  • Literature review of pharmacological interventions for obesity.
  • Analysis of FDA-approved and repurposed drug data.
  • Synthesis of evidence on combination therapy approaches.

Main Results:

  • Several pharmacologic options are available for obesity treatment.
  • Drugs approved for other conditions show efficacy in weight management.
  • Individualized treatment plans are crucial for optimal outcomes.

Conclusions:

  • Pharmacological therapy for obesity is advancing with diverse options.
  • Optimal obesity treatment necessitates a combination of behavioral, nutritional, pharmacologic, endoscopic, and surgical modalities.
  • Personalized therapeutic strategies are key to addressing the complexity of obesity.